Don't be mis-guided when the data are silent and the editorial misses the mark.

Thomas, Cheryl; Williams, Tyrone; Turrisi, Andrew T.

doi:10.1200/jco.1998.16.4.1631

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The survival of lung cancer patients after tumor detection is typically less than 5% at five years [35]. Recently, evidence has started to show that CAR might have a role in cancer therapy [19], [20].…”

Section: Discussionmentioning

confidence: 99%

“…Lung cancer continues to be a major problem for health-care systems worldwide, as most cases involve patients with comprised lung function, metastasis, multi-drug resistance and poor outcomes. The survival of lung cancer patients after tumor detection is typically less than 5% at five years [35] . Recently, evidence has started to show that CAR might have a role in cancer therapy [19] , [20] .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Constitutive Androstane Receptor Ligands Modulate the Anti-Tumor Efficacy of Paclitaxel in Non-Small Cell Lung Cancer Cells

et al. 2014

View full text Add to dashboard Cite

BackgroundLung tumors are the leading cause of cancer deaths worldwide and paclitaxel has proven to be useful for patients with lung cancer, however, acquired resistance is a major problem. To overcome this problem, one promising option is the use of Constitutive Androstane Receptor (CAR) ligands in combination with chemotherapeutics against cancer cells. Therefore, we wish to elucidate the effects of CAR ligands on the antineoplastic efficacy of paclitaxel in lung cancer cells.Methodology/Principal FindingsOur results from cell viability assays exposing CAR agonist or inverse-agonist to mouse and human lung cancer cells modulated the antineoplastic effect of paclitaxel. The CAR agonists increased the effect of Paclitaxel in 6 of 7 lung cancer cell lines, whereas the inverse-agonist had no effect on paclitaxel cytotoxicity. Interestingly, the mCAR agonist TCPOBOP enhanced the expression of two tumor suppressor genes, namely WT1 and MGMT, which were additively enhanced in cells treated with CAR agonist in combination with paclitaxel. Also, in silico analysis showed that both paclitaxel and CAR agonist TCPOBOP docked into the mCAR structure but not the inverse agonist androstenol. Paclitaxel per se increases the expression of CAR in cancer cells. At last, we analyzed the expression of CAR in two public independent studies from The Cancer Genome Atlas (TCGA) of Non Small Cell Lung Cancer (NSCLC). CAR is expressed in variable levels in NSCLC samples and no association with overall survival was noted.Conclusions/SignificanceTaken together, our results demonstrated that CAR agonists modulate the antineoplastic efficacy of paclitaxel in mouse and human cancer cell lines. This effect was probably related by the enhanced expression of two tumor suppressor genes, viz. WT1 and MGMT. Most of NSCLC cases present CAR gene expression turning it possible to speculate the use of CAR modulation by ligands along with Paclitaxel in NSCLC therapy.

show abstract

Section: Discussionmentioning

confidence: 99%